INTELGENXHome  >  Investors  >  Press Releases
INTELGENXHome  >  Investors  >  Press Releases
2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005
IntelGenx Achieves Positive Bioequivalence Results With Novel Anti-Migraine Film November 17, 2009
IntelGenx Reports Results For the Third Quarter and Nine Months Ended September 30, 2009 November 10, 2009
IntelGenx Determines Exercise Price of Stock Options to IR Firm October 6, 2009
IntelGenx Strengthens Investor Relations Activities October 1, 2009
IntelGenx Technologies Corp. Completes Additional Private Placement September 4, 2009
IntelGenx Technologies Corp. Announces Shareholder Call August 31, 2009
IntelGenx Corp. Comments on CPI-300 Patent Infringement Complaint August 21, 2009
IntelGenx Reports Results for the Second Quarter and Six Months Ended June 30, 2009 August 14, 2009
IntelGenx Technologies Corp. Files Preliminary Short Form Prospectus; IntelGenx Completes Additional Private Placement July 29, 2009
IntelGenx Technologies Corp. Announces Closing of Private Placement July 14, 2009
IntelGenx Corp. Announces FDA Acceptance for Filing of NDA for CPI-300 Antidepressant June 23, 2009
IntelGenx Corp. and Circ Pharma to Commence Phase 1 Proof-of-Concept Study of CRES Pravastatin, a Novel Low Dose Formulation Containing Pravastatin for the Treatment of Hyperlipidemia May 19, 2009
IntelGenx Reports Results for the First Quarter of 2009 May 13, 2009
Positive Bioequivalence Results for IntelGenx Developed Product April 20, 2009
IntelGenx Announces Appointment of New Director April 15, 2009
Cannasat and IntelGenx Announce Positive Phase 1(b) Results Improved buccal tablet outperforms oral dronabinol April 14, 2009
IntelGenx Corp. and Cary Pharmaceuticals file NDA for CPI-300 antidepressant April 7, 2009
IntelGenx Technologies Corp. Announces 2008 Annual Financial Results March 25, 2009
Cannasat Therapeutics and IntelGenx Corp. Reach Key Milestone January 28, 2009
IntelGenx Corp. and Circ Pharma Ltd announced today a partnership to develop and commercialise a novel drug for the treatment of hyperlipidemia. January 19, 2009

Shareholder Tools

Financial Reports E-mail Alerts RSS News Feeds

About us

Product

R&D Services

Manufacturing Services

Partnering

Investors

More Links

© Copyright 2017. IntelGenx Corp. All Rights Reserved.
Powered By Q4 Inc. 5.15.0.14